Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer's disease

Alzheimer's and Dementia

Volumn 13, Issue 5, 2017, Pages 510-519

  Mastroeni, Diego ^a,b   Khdour, Omar M ^c   Delvaux, Elaine ^a   Nolz, Jennifer ^a   Olsen, Gary ^b   Berchtold, Nicole ^d   Cotman, Carl ^d   Hecht, Sidney M ^c   Coleman, Paul D ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Alzheimer's disease; Microarray; Mild cognitively impaired (MCI); Mitochondria; Oxidative phosphorylation related genes expression; Postmortem brains

Indexed keywords

CELL NUCLEUS DNA; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HIPPOCAMPAL TISSUE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL GENE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; AUTOPSY; COGNITIVE DEFECT; DNA MICROARRAY; GENETICS; HIPPOCAMPUS; MITOCHONDRION; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AUTOPSY; COGNITION DISORDERS; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MITOCHONDRIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE PHOSPHORYLATION;

EID: 85007390015     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.09.003     Document Type: Article

References (76)

1. [1] Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11 (2015), 332–384.
2. [2] Hauptmann, S., Scherping, I., Dröse, S., Brandt, U., Schultz, K.L., Jendrach, M., et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30 (2009), 1574–1586.
3. [3] Du, H., Guo, L., Yan, S., Sosunov, A.A., McKhann, G.M., Yan, S.S., Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A 107 (2010), 18670–18675.
4. [4] Yao, J., Irwin, R.W., Zhao, L., Nilsen, J., Hamilton, R.T., Brinton, R.D., Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106 (2009), 14670–14675.
5. [5] Reddy, P.H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T.P., Anekonda, V., et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822 (2012), 639–649.
6. [6] Xie, H., Guan, J., Borrelli, L.A., Xu, J., Serrano-Pozo, A., Bacskai, B.J., Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. J Neurosci 33 (2013), 17042–17051.
7. [7] Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., Strosznajder, J.B., et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?. Antioxid Redox Signal 9 (2007), 1659–1675.
8. [8] Pedrós, I., Petrov, D., Allgaier, M., Sureda, F., Barroso, E., Beas-Zarate, C., et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochim Biophys Acta 1842 (2014), 1556–1566.
9. [9] Calkins, M.J., Manczak, M., Mao, P., Shirendeb, U., Reddy, P.H., Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20 (2011), 4515–4529.
10. [10] Parihar, M.S., Brewer, G.J., Mitoenergetic failure in Alzheimer's disease. Am J Physiol Cell Physiol 292 (2007), C8–C23.
11. [11] McBride, H.M., Neuspiel, M., Wasiak, S., Mitochondria: more than just a powerhouse. Curr Biol, 16, 2006, R551.
12. [12] Graier, W.F., Frieden, M., Malli, R., Mitochondria and Ca2+ signaling: old guest, new functions. Pflugers Arch 455 (2007), 375–396.
13. [13] Bras, M., Queenan, B., Susin, S.A., Programmed cell death via mitochondria different modes of dying. Biochemistry (Mosc) 70 (2005), 231–239.
14. [14] Pradelli, L.A., Beneteau, M., Ricci, J.E., Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci 67 (2010), 1589–1597.
15. [15] Henze, K., Martin, W., Evolutionary biology: essence of mitochondria. Nature 426 (2003), 127–128.
16. [16] Saraste, M.W., Oxidative phosphorylation at the fin de siècle. Science 283 (1999), 1488–1493.
17. [17] Mitchell, P., Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 191 (1961), 144–148.
18. [18] Newmeyer, D.D., Ferguson-Miller, S., Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112 (2003), 481–490.
19. [19] Anderson, S., Bankier, A.T., Barrell, B.G., de Bruijn, M.H., Coulson, A.R., Drouin, J., et al. Sequence and organization of the human mitochondrial genome. Nature 290 (1981), 457–465.
20. [20] Attardi, G., Chomyn, A., Montoya, J., Ojala, D., Identification and mapping of human mitochondrial genes. Cytogenet Cell Genet 32 (1982), 85–98.
21. [21] Wallace, D.C., Mitochondrial diseases in man and mouse. Science 283 (1999), 1482–1488.
22. [22] Manczak, M., Anekonda, T.S., Henson, E., Park, B.S., Quinn, J., Reddy, P.H., Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15 (2006), 1437–1449.
23. [23] Cha, M.Y., Han, S.H., Son, S.M., Hong, H.S., Choi, Y.J., Byun, J., et al. Mitochondria-specific accumulation of amyloid beta induces mitochondrial dysfunction leading to apoptotic cell death. PLoS One, 7, 2012, e34929.
24. [24] Rhein, V., Song, X., Wiesner, A., Ittner, L.M., Baysang, G., Meier, F., et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 106 (2009), 20057–20062.
25. [25] Parker, W.D., Parks, J.K., Filley, C.M., Kleinschmidt- DeMasters, B.K., Electron transport chain defects in Alzheimer's disease brain. Neurology 44 (1994), 1090–1096.
26. [26] Rhein, V., Baysang, G., Rao, S., Meier, F., Bonert, A., Müller-Spahn, F., et al. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29 (2009), 1063–1071.
27. [27] Chandrasekaran, K., Hatanpaa, K., Brady, D.R., Rapoport, S.I., Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp Neurol 142 (1996), 80–88.
28. [28] Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J.W., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19 (2005), 2040–2041.
29. [29] Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 (2001), 759–767.
30. [30] Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q., Lee, V.M., Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21 (2001), 4183–4187.
31. [31] Lin, M.T., Simon, D.K., Ahn, C.H., Kim, L.M., Beal, M.F., High aggregate burden of somatic mtDNA point mutation in aging and Alzheimer's disease brain. Hum Mol Genet 11 (2002), 133–145.
32. [32] Liang, W.S., Reiman, E.M., Valla, J., Dunckley, T., Beach, T.G., Grover, A., et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A 105 (2008), 4441–4446.
33. [33] Manczak, M., Park, B.S., Jung, Y., Reddy, P.H., Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5 (2004), 147–162.
34. [34] Chandrasekaran, K., Giordano, T., Brady, D.R., Stoll, J., Martin, L.J., Rapoport, S.I., Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res Mol Brain Res 24 (1994), 336–340.
35. [35] Chandrasekaran, K., Hatanpää, K., Brady, D.R., Stoll, J., Rapoport, S.I., Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Brain Res 796 (1996), 13–19.
36. [36] Chandrasekaran, K., Hatanpää, K., Rapoport, S.I., Brady, D.R., Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Brain Res Mol Brain Res 44 (1997), 99–104.
37. [37] Rice, A.C., Ladd, A.C., Bennett, J.P., Postmortem Alzheimer's disease hippocampi show oxidative phosphorylation gene expression opposite that of isolated pyramidal neurons. J Alzheimers Dis 45 (2015), 1051–1059.
38. [38] Berchtold, N.C., Cribbs, D.H., Coleman, P.D., Rogers, J., Head, E., Kim, R., et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A 105 (2008), 15605–15610.
39. [39] Berchtold, N., Sabbagh, M., Beach, T., Kim, R., Cribbs, D., Cotman, C., Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. Neurobiol Aging 35 (2014), 1961–1972.
40. [40] Manczak, M., Jung, Y., Park, B.S., Partovi, D., Reddy, P.H., Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem 92 (2005), 494–504.
41. [41] Lee, C.K., Weindruch, R., Prolla, T.A., Gene-expression profile of the ageing brain in mice. Nat Genet 25 (2000), 294–297.
42. [42] Blalock, E.M., Chen, K.C., Sharrow, K., Herman, J.P., Porter, N.M., Foster, T.C., et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23 (2003), 3807–3819.
43. [43] Fraser, H.B., Khaitovich, P., Plotkin, J.B., Paabo, S., Eisen, M.B., Aging and gene expression in the primate brain. PLoS Biol, 3, 2005, e274.
44. [44] Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20 (2010), S265–S279.
45. [45] Johri, A., Calingasan, N.Y., Hennessey, T.M., Sharma, A., Yang, L., Wille, E., et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 21 (2012), 1124–1137.
46. [46] Podlesniy, P., Figueiro-Silva, J., Llado, A., Antonell, A., Sanchez-Valle, R., Alcolea, D., et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 74 (2013), 655–668.
47. [47] Dowling, N.M., Johnson, S.C., Gleason, C.E., Jagust, W.J., The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Neuroimage 105 (2015), 357–368.
48. [48] Demetrius, L.A., Magistretti, P.J., Pellerin, L., Alzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect. Front Physiol, 5, 2015, 522.
49. [49] Grimm, A., Friedland, K., Eckert, A., Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease. Biogerontology 17 (2016), 281–296.
50. [50] Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L., Kuhl, D.E., Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42 (1997), 85–94.
51. [51] Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56 (2001), 127–129.
52. [52] Weaver, C.L., Espinoza, M., Kress, Y., Davies, P., Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21 (2000), 719–727.
53. [53] Nixon, R.A., Cataldo, A.M., Mathews, P.M., The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: A review. Neurochem Res 25 (2000), 1161–1172.
54. [54] Frost, B., Diamond, M.I., Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11 (2010), 155–159.
55. [55] Tai, H.C., Wang, B.Y., Serrano-Pozo, A., Frosch, M.P., Spires-Jones, T.L., Hyman, B.T., Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. Acta Neuropathol Commun, 2, 2014, 146.
56. [56] Cheung, G., Jupp, O.J., Cousin, M.A., Activity-dependent bulk endocytosis and clathrin-dependent endocytosis replenish specific synaptic vesicle pools in central nerve terminals. J Neurosci 30 (2010), 8151–8161.
57. [57] Mastroeni, D., Delvaux, E., Nolz, J., Tan, Y., Grover, A., Oddo, S., et al. Aberrant intracellular localization of H3k4me3 demonstrates an early epigenetic phenomenon in Alzheimer's disease. Neurobiol Aging 36 (2015), 3121–3129.
58. [58] Currais, A., Hortobágyi, T., Soriano, S., The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer's disease. Aging 1 (2009), 363–371.
59. [59] Mu, Y., Gage, F.H., Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener, 6, 2011, 85.
60. [60] Ashraf, A., Fan, Z., Brooks, D.J., Edison, P., Cortical hypermetabolism in MCI subjects: A compensatory mechanism?. Eur J Nucl Med Mol Imaging 42 (2015), 447–458.
61. [61] Saura, C.A., Parra-Damas, A., Enriquez-Barreto, L., Gene expression parallels synaptic excitability and plasticity changes in Alzheimer's disease. Front Cell Neurosci, 9, 2015, 318.
62. [62] Del Sole, A., Clerici, F., Chiti, A., Lecchi, M., Mariani, C., Maggiore, L., et al. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging 35 (2008), 1357–1366.
63. [63] Bobba, A., Petragallo, V.A., Marra, E., Atlante, A., Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease. Int J Alzheimers Dis, 2010, 2010.
64. [64] Cavallucci, V., Berretta, N., Nobili, A., Nisticò, R., Mercuri, N., D'Amelio, M., Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer's disease. Neuromolecular Med 15 (2013), 541–548.
65. [65] Ma, T., Trinh, M.A., Wexler, A.J., Bourbon, C., Gatti, E., Pierre, P., et al. Suppression of eIF2a kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci 16 (2013), 1299–1305.
66. [66] Gleichmann, M., Mattson, M., Neuronal calcium homeostasis and dysregulation. Antioxid Redox Signal 14 (2011), 1261–1273.
67. [67] Lin, M.T., Beal, M.F., Alzheimer's APP mangles mitochondria. Nat Med 12 (2006), 1241–1243.
68. [68] Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006), 787–795.
69. [69] Cardoso, S.M., Santos, S., Swerdlow, R.H., Oliveira, C.R., Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J 15 (2001), 1439–1441.
70. [70] Veereshwarayya, V., Kumar, P., Rosen, K.M., Mestril, R., Querfurth, H.W., Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular beta-amyloid-induced inhibition of complex IV and limit apoptosis. J Biol Chem 281 (2006), 29468–29478.
71. [71] Camilleri, A., Zarb, C., Caruana, M., Ostermeier, U., Ghio, S., Högenc, T., et al. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta 1828 (2013), 2532–2543.
72. [72] Sanz-Blasco, S., Valero, R.A., Rodriguez-Crespo, I., Villalobos, C., Nunez, L., Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One, 3, 2008, e2718.
73. [73] Moreira, P.I., Carvalho, C., Zhu, X., Smith, M.A., Perry, G., Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802 (2010), 2–10.
74. [74] Falkenberg, M., Larsson, N.G., Gustafsson, C.M., DNA replication and transcription in mammalian mitochondria. Annu Rev Biochem 76 (2007), 679–699.
75. [75] She, H., Yang, Q., Shepherd, K., Smith, Y., Miller, G., Testa, C., et al. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest 121 (2011), 930–940.
76. [76] Mastroeni, D., Khdour, O.M., Arce, P.M., Hecht, S.M., Coleman, P.D., Novel antioxidants protect mitochondria from the effects of oligomeric amyloid Beta and contribute to the maintenance of epigenome function. ACS Chem Neurosci 15 (2015), 588–598.